TRIO - Translational Research in Oncology

For the fourth year in a row, TRIO joined the Institut Curie as part of a new edition of its national campaign “A Daffodil Against Cancer”, by participating in the “Course de la Jonquille Contre le Cancer”, to support cancer research. This time, TRIO ranked in 80th place out of 917 organizations! TRIO is proud to participate in this worthy cause.

We're #hiring a new Senior Clinical Research Associate-Freelance in Porto Alegre, Rio Grande do Sul. Apply today or share this post with your network.

We're #hiring a new Senior Clinical Research Associate-Freelance in Argentina. Apply today or share this post with your network.

March is Colorectal Cancer Awareness Month. Colorectal cancer is the third most frequently diagnosed cancer worldwide and a significant cause of death despite advances in prevention, early diagnosis and treatment.     Did you know TRIO has a Gastrointestinal Cancers Scientific Committee? This Scientific Committee, chaired by Dr.Zev Wainberg, supports TRIO’s mission of changing the lives of cancer patients by conducting trials that make a difference. TRIO is collaborating with TORL Biotherapeutics, LLC to conduct a Phase I trial evaluating an antibody-drug conjugate directed against cadherin 17 in patients with colorectal cancer. Innovation brings us closer to more effective and life-saving treatments for colorectal cancer patients

TRIO is honored to welcome Mark Pegram, MD to the TRIO Breast Cancer Scientific Committee. Dr. Pegram is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute. He also serves as Associate Dean for Clinical Research Quality at the Stanford University School of Medicine, and is the Medical Director of the Stanford Clinical Translational Research Unit. We are very proud to have Dr. Pegram on board and look forward to working together to advance cancer research and continue to shape the field of precision medicine for breast cancer patients.

For the third year in a row, the TRIO Latin American hub has ranked among the best workplaces in Uruguay by Great Place to Work®! At TRIO, we strive to create a supportive, friendly and healthy team environment where our clinical research professionals can collaborate, thrive and do their best work. Here's to many more years of growth, collaboration and shared success! 

We're #hiring a new Data Manager in Edmonton, Alberta. Apply today or share this post with your network.

We're #hiring a new Data Manager in Toronto, Ontario. Apply today or share this post with your network.

This year, “Accelerate Action for gender equality” is the International Women's Day campaign theme. This theme calls for action that can unlock equal rights, power, and opportunities for all and a future where no one is left behind. This International Women’s Day, TRIO reaffirms its commitment to strengthen inclusivity and accelerate action towards gender parity.     At TRIO, 76% of our staff and 66% of our senior leadership are women and we will continue to encourage a work culture that celebrates equal opportunities for everyone in our organization.   

World Triple Negative Breast Cancer Day, held on March 3rd, is a reminder that triple-negative breast cancers (TNBC) remain the most difficult to treat breast cancer subtype. #TNBC accounts for about 10-15% of all breast cancers and continues to be the subtype with the highest recurrence and mortality rates. This is primarily due to the lack of three key receptors essential for targeted endocrine and HER2-directed therapies (Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor 2 Receptor).    Treatment of TNBC can be challenging but progress is being made. Advances in immunotherapy and precision medicine as well as a dynamic research landscape, are bringing hope of curing more patients. At TRIO, we are committed to changing the lives of cancer patients by conducting trials that make a difference. Let´s raise awareness, support research, and stand with those affected by TNBC.